Overview Dividends

(CDNA) CareDx - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US14167L1035

Kidney, Heart, Transplant, Diagnostics, AlloMap

CDNA EPS (Earnings per Share)

EPS Growth (3Y CAGR): 17.86%
EPS Trend (3Y Correlation): 64.5%

CDNA Revenue

Revenue Growth (3Y CAGR): 3.26%
Revenue Trend (3Y Correlation): 44.5%

Description: CDNA CareDx August 24, 2025

CareDx Inc (NASDAQ:CDNA) is a biotechnology company listed on the NASDAQ exchange, operating in the United States. The companys stock is classified as common stock.

To understand the companys financial health, we need to examine its income tax expense on a yearly basis. A thorough analysis of this metric can reveal insights into the companys profitability and tax management strategies.

CareDxs market capitalization stands at $630.74 million, indicating a relatively small-cap company with a certain level of market presence. The price-to-earnings ratio is 11.29, suggesting that the stock may be undervalued relative to its earnings. Return on Equity (RoE) is 15.22%, indicating a decent return for shareholders.

Key economic drivers for CareDx include the demand for its biotechnology products or services, competition in the industry, and regulatory developments. Key Performance Indicators (KPIs) to monitor include revenue growth, gross margin, research and development expenses as a percentage of revenue, and cash flow generation. The companys ability to innovate and bring new products to market will be crucial in driving future growth.

Investors should also consider the companys burn rate, cash reserves, and funding requirements to assess its financial sustainability. With a beta of 2.221, CareDxs stock price is expected to be relatively volatile, making it essential for investors to monitor market trends and adjust their strategies accordingly.

CDNA Stock Overview

Market Cap in USD	798m
Sub-Industry	Biotechnology
IPO / Inception	2014-07-17

CDNA Stock Ratings

Growth Rating	-45.0%
Fundamental	50.1%
Dividend Rating	-
Return 12m vs S&P 500	-42.6%
Analyst Rating	4.13 of 5

CDNA Dividends

Currently no dividends paid

CDNA Growth Ratios

Growth Correlation 3m	77.4%
Growth Correlation 12m	-84.6%
Growth Correlation 5y	-59.2%
CAGR 5y	0.61%
CAGR/Max DD 3y (Calmar Ratio)	0.01
CAGR/Mean DD 3y (Pain Ratio)	0.02
Sharpe Ratio 12m	0.55
Alpha	-68.15
Beta	2.371
Volatility	100.67%
Current Volume	1435k
Average Volume 20d	1130.3k
Stop Loss	14.6 (-6.5%)
Signal	0.04

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (51.7m TTM) > 0 and > 6% of Revenue (6% = 20.4m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA 8.80pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 62.82% (prev 81.55%; Δ -18.73pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.04 (>3.0%) and CFO 17.7m <= Net Income 51.7m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.30 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (54.3m) change vs 12m ago 4.04% (target <= -2.0% for YES)

Gross Margin 66.71% (prev 64.56%; Δ 2.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 74.82% (prev 63.65%; Δ 11.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -0.39 (EBITDA TTM -19.9m / Interest Expense TTM -100.8m) >= 6 (WARN >= 3)

Altman Z'' -8.82

(A) 0.48 = (Total Current Assets 307.3m - Total Current Liabilities 93.2m) / Total Assets 444.3m

(B) -1.56 = Retained Earnings (Balance) -695.2m / Total Assets 444.3m

warn (B) unusual magnitude: -1.56 — check mapping/units

(D) -6.00 = Book Value of Equity -701.2m / Total Liabilities 116.9m

Total Rating: -8.82 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 50.10

1. Piotroski 4.50pt = -0.50

2. FCF Yield 2.78% = 1.39

3. FCF Margin 5.24% = 1.31

4. Debt/Equity 0.09 = 2.50

5. Debt/Ebitda 1.96 = 0.08

6. ROIC - WACC (= -25.94)% = -12.50

7. RoE 15.22% = 1.27

8. Rev. Trend 44.52% = 3.34

9. EPS Trend 64.45% = 3.22

What is the price of CDNA shares?

As of November 09, 2025, the stock is trading at USD 15.62 with a total of 1,435,003 shares traded.
Over the past week, the price has changed by +4.13%, over one month by +6.48%, over three months by +29.41% and over the past year by -34.59%.

Is CareDx a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, CareDx is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 50.10 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CDNA is around 13.77 USD . This means that CDNA is currently overvalued and has a potential downside of -11.84%.

Is CDNA a buy, sell or hold?

CareDx has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy CDNA.

Strong Buy: 4
Buy: 1
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CDNA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	21.8	39.8%
Analysts Target Price	21.8	39.8%
ValueRay Target Price	16.2	3.6%

CDNA Fundamental Data Overview November 02, 2025

Market Cap USD = 798.4m (798.4m USD * 1.0 USD.USD)
P/E Trailing = 14.2857
P/E Forward = 78.125
P/S = 2.3426
P/B = 2.4128
P/EG = -0.12
Beta = 2.371
Revenue TTM = 340.8m USD
EBIT TTM = -39.1m USD
EBITDA TTM = -19.9m USD
Long Term Debt = 29.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.34m USD (from shortTermDebt, last quarter)
Debt = 29.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -39.1m USD (from netDebt column, last quarter)
Enterprise Value = 641.3m USD (798.4m + Debt 29.1m - CCE 186.3m)
Interest Coverage Ratio = -0.39 (Ebit TTM -39.1m / Interest Expense TTM -100.8m)
FCF Yield = 2.78% (FCF TTM 17.8m / Enterprise Value 641.3m)
FCF Margin = 5.24% (FCF TTM 17.8m / Revenue TTM 340.8m)
Net Margin = 15.16% (Net Income TTM 51.7m / Revenue TTM 340.8m)
Gross Margin = 66.71% ((Revenue TTM 340.8m - Cost of Revenue TTM 113.5m) / Revenue TTM)
Gross Margin QoQ = 66.19% (prev 66.45%)
Tobins Q-Ratio = 1.44 (Enterprise Value 641.3m / Total Assets 444.3m)
Interest Expense / Debt = 9.86% (Interest Expense 2.87m / Debt 29.1m)
Taxrate = 1.35% (-117.0k / -8.69m)
NOPAT = -38.6m (EBIT -39.1m * (1 - 1.35%)) [loss with tax shield]
Current Ratio = 3.30 (Total Current Assets 307.3m / Total Current Liabilities 93.2m)
Debt / Equity = 0.09 (Debt 29.1m / totalStockholderEquity, last quarter 327.4m)
Debt / EBITDA = 1.96 (negative EBITDA) (Net Debt -39.1m / EBITDA -19.9m)
Debt / FCF = -2.19 (Net Debt -39.1m / FCF TTM 17.8m)
Total Stockholder Equity = 339.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.63% (Net Income 51.7m / Total Assets 444.3m)
RoE = 15.22% (Net Income TTM 51.7m / Total Stockholder Equity 339.6m)
RoCE = -10.61% (EBIT -39.1m / Capital Employed (Equity 339.6m + L.T.Debt 29.1m))
RoIC = -11.36% (negative operating profit) (NOPAT -38.6m / Invested Capital 339.6m)
WACC = 14.57% (E(798.4m)/V(827.5m) * Re(14.75%) + D(29.1m)/V(827.5m) * Rd(9.86%) * (1-Tc(0.01)))
Discount Rate = 14.75% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.70%
[DCF Debug] Terminal Value 46.69% ; FCFE base≈17.8m ; Y1≈11.7m ; Y5≈5.36m
Fair Price DCF = 0.95 (DCF Value 50.6m / Shares Outstanding 53.2m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 64.45 | EPS CAGR: 17.86% | SUE: 0.70 | # QB: 0
Revenue Correlation: 44.52 | Revenue CAGR: 3.26% | SUE: -0.47 | # QB: 0

Additional Sources for CDNA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle